Luo Liwen, Zhang Hongyu, Nian Songwen, Lv Chaoqun, Ni Bing, Wang Dan, Tian Zhiqiang
*Department of Pathophysiology and High Altitude Pathology, †Institute of Immunology, PLA, and ‡Battalion 13 of Cadet Brigade, Third Military Medical University; §Department of Emergency, The Second Affiliated Hospital of Chongqing Medical University; and ∥Department of Obstetrics and Gynecology, Southwest Hospital, Third Military Medical University, Chongqing, China.
Int J Gynecol Cancer. 2017 Sep;27(7):1422-1430. doi: 10.1097/IGC.0000000000001032.
Transcription factor 3 (TCF3, or E2A) is a multifunctional bHLH (basic helix loop helix) transcription factor. The role of TCF3 expression in cancer and the multiple cell signaling pathways that regulate or are influenced by TCF3 are unclear. Therefore, the expression level of TCF3 in patients with cervical squamous cell carcinoma (CSCC) is discussed in this study.
Total RNA was extracted using real-time quantitative reverse transcription-polymerase chain reaction. Western blotting was applied to confirm the results. Immunohistochemistry was used to characterize the expression patterns of TCF3 in CSCC specimens. The close relationship between the expression levels of TCF3 and the 5-year overall survival time was described by survival curves. The association between TCF3 expression and clinicopathological characteristics of 119 CSCC patients was analyzed by Chi-square, Fisher exact test, and Cox regression analysis. TCF3 was overexpressed or inhibited by plasmid transfection, and the proliferation, invasion, and migration of cells were detected using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), wound healing, and Transwell assays.
The expression of TCF3 was higher in CSCC tissues than in nonmalignant cervical tissues. Messenger RNA (mRNA) and protein in patient tissues were increased compared with nonmalignant cervical tissues. Moreover, the level of expression in early-stage disease was higher than in the advanced stage. From FIGO (International Federation of Gynecology and Obstetrics) stages I to IV, immunohistochemistry staining intensity gradually increased. A high level of expression was closely related to clinical stages. The expression of TCF3 was negatively correlated with overall survival time. TCF3 can promote HeLa cell growth, invasion, and migration in vitro.
Based on our results, TCF3 is clearly associated with the progression of CSCC. This is the first time that it has been reported that TCF3 can act as a tumor promoter in cervical cancer and thus might be of great significance in the prognosis of CSCC.
转录因子3(TCF3,即E2A)是一种多功能碱性螺旋-环-螺旋(bHLH)转录因子。TCF3表达在癌症中的作用以及调节或受TCF3影响的多种细胞信号通路尚不清楚。因此,本研究探讨了宫颈鳞状细胞癌(CSCC)患者中TCF3的表达水平。
采用实时定量逆转录-聚合酶链反应提取总RNA。应用蛋白质印迹法确认结果。免疫组织化学用于表征CSCC标本中TCF3的表达模式。生存曲线描述了TCF3表达水平与5年总生存时间之间的密切关系。采用卡方检验、Fisher精确检验和Cox回归分析,分析119例CSCC患者的TCF3表达与临床病理特征之间的相关性。通过质粒转染过表达或抑制TCF3,并使用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐(MTT)、伤口愈合试验和Transwell试验检测细胞的增殖、侵袭和迁移能力。
CSCC组织中TCF3的表达高于非恶性宫颈组织。与非恶性宫颈组织相比,患者组织中的信使核糖核酸(mRNA)和蛋白质增加。此外,早期疾病的表达水平高于晚期。从国际妇产科联盟(FIGO)I期到IV期,免疫组织化学染色强度逐渐增加。高表达水平与临床分期密切相关。TCF3的表达与总生存时间呈负相关。TCF3在体外可促进HeLa细胞的生长、侵袭和迁移。
基于我们的结果,TCF3显然与CSCC的进展相关。首次报道TCF3在宫颈癌中可作为肿瘤促进因子,因此可能对CSCC的预后具有重要意义。